1
|
Pan XY, Liu XJ, Li J, Zhen SJ, Liu DX, Feng Q, Zhao WX, Luo Y, Zhang YL, Li HW, Yang JL. The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300. Gene Ther 2016; 24:40-48. [PMID: 27834948 DOI: 10.1038/gt.2016.74] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 10/21/2016] [Accepted: 11/01/2016] [Indexed: 11/09/2022]
Abstract
Ras mutations and overexpression of the Ras protein, p21Ras, are main causes of cancer development and progression, which has made the Ras gene and p21Ras important targets for therapy of Ras-driven cancers. We previously prepared recombinant adenovirus KGHV100 based on replication-defective adenovirus type 5, which could intracellularly express anti-p21Ras single chain fragment viable antibodies (scFv) and repress tumor growth in vitro and in vivo. However, the anti-tumor effects of this anti-p21Ras scFv were limited by short-term scFv expression due to a replication defect of KGHV100. To enhance the anti-tumor efficacy and safety of anti-p21Ras scFv, the present study constructed a dual-promoter-regulated recombinant adenovirus KGHV300 that carried anti-p21Ras scFv. In KGHV300, the expression levels of the essential replication genes E1a and E1b, were controlled by the human telomerase reverse transcriptase promoter and the hypoxia response element, respectively, and the anti-p21Ras scFv gene was controlled by the cytomegalovirus promoter. The conditional replication of KGHV300 and its antitumor efficacy were characterized in several tumor cell lines in vitro and in xenograft models of human breast cancer in nude mice. TCID50 assay demonstrated that KGHV300 could replicate in tumor cell lines but not in normal cell lines. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay indicated that the growth of tumor cells was effectively inhibited by KGHV300 infection. In MDA-MB-231 tumor xenograft models, KGHV300 effectively and significantly inhibited tumor growth and induced apoptosis of tumor cells. We concluded that the recombinant adenovirus KGHV300 may be a more potent and safer antitumor therapeutic for Ras-driven cancer biotherapy.
Collapse
Affiliation(s)
- X Y Pan
- Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China
| | - X J Liu
- Graduate School, Kunming Medical University, Kunming, Yunnan Province, China
| | - J Li
- Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming, Yunnan Province, China
| | - S J Zhen
- Graduate School, Kunming Medical University, Kunming, Yunnan Province, China
| | - D X Liu
- Graduate School, Kunming Medical University, Kunming, Yunnan Province, China
| | - Q Feng
- Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China
| | - W X Zhao
- Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China
| | - Y Luo
- Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming, Yunnan Province, China
| | - Y L Zhang
- Biotechnique College, Southern Medical University, Guangzhou, Guangdong Province, China
| | - H W Li
- Biotechnique College, Southern Medical University, Guangzhou, Guangdong Province, China
| | - J L Yang
- Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China.,Graduate School, Kunming Medical University, Kunming, Yunnan Province, China.,Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming, Yunnan Province, China
| |
Collapse
|
2
|
Yang JL, Liu DX, Zhen SJ, Zhou YG, Zhang DJ, Yang LY, Chen HB, Feng Q. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues. BMC Cancer 2016; 16:131. [PMID: 26897358 PMCID: PMC4761205 DOI: 10.1186/s12885-016-2168-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2015] [Accepted: 02/14/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The ras genes play an important role in the development and progression of human tumours. Neutralizing Ras proteins in the cytoplasm could be an effective approach to blocking ras signalling. In this study, we prepared anti-p21Ras single chain fragment variable antibody (scFv) and investigated its immunoreactivity with human tumours. METHODS The coding sequences of H-ras, K-ras, and N-ras were separately ligated into the vector pET-28a(+). Then, recombinant expressing plasmids were induced by IPTG for p21Ras expression in E. coli. Hybridoma cell lines producing anti-p21Ras monoclonal antibodies were isolated using wildtype p21Ras proteins as immunogens. Anti-p21Ras scFv antibody was prepared from the hybridoma by the phage scFv display method. The immunoreactivity of the anti-p21Ras monoclonal antibody and the scFv antibody was identified by ELISA and immunocytochemistry. RESULTS We prokaryotically expressed wildtype H-p21Ras, K-p21Ras and N-p21Ras and generated the hybridoma cell line KGH-R1, producing anti-p21Ras monoclonal antibodies. It was demonstrated that KGH-R1 monoclonal antibody could recognize wildtype and mutated H-p21Ras, K-p21Ras and N-p21Ras in human tumour cell lines. In all 14 types of primary human cancer tissues tested, the monoclonal antibody presented strong immunoreactivity but showed weak or negative immunoreactivity in the corresponding normal tissues. Subsequently, we prepared anti-p21Ras scFv from hybridoma KGH-R1, which showed the same immunoreactivity as the original monoclonal antibody. Sequence analysis demonstrated that the nucleotides and amino acids of the scFv exhibited an approximately 50 % difference from the anti-p21Ras scFv reported previously. CONCLUSIONS This study presents a novel anti-p21Ras scFv antibody. Our data suggest that the scFv may be useful for ras signalling blockage and may be a potential therapeutic antibody for ras-derived tumours.
Collapse
Affiliation(s)
- Ju-Lun Yang
- Department of Pathology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China.
| | - Du-Xian Liu
- Department of Molecular Biology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China
| | - Shi-Jian Zhen
- Department of Molecular Biology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China
| | - Yun-Gang Zhou
- Department of Molecular Biology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China
| | - Dai-Jun Zhang
- Department of Pathology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China
| | - Li-Ying Yang
- Department of Pathology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China
| | - Hao-Bing Chen
- Department of Pathology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China
| | - Qiang Feng
- Department of Pathology, Kunming General Hospital/Kunming Medical University, Kunming, 650032, Yunnan Province, China
| |
Collapse
|
3
|
Yang JL, Pan XY, Zhao WX, Hu QC, Ding F, Feng Q, Li GY, Luo Y. The antitumor efficacy of a novel adenovirus-mediated anti-p21Ras single chain fragment variable antibody on human cancers in vitro and in vivo. Int J Oncol 2016; 48:1218-28. [PMID: 26780944 DOI: 10.3892/ijo.2016.3334] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Accepted: 10/23/2015] [Indexed: 11/05/2022] Open
Abstract
Activated ras genes are found in a large number of human tumors, and therefore are one of important targets for cancer therapy. This study investigated the antitumor effects of a novel single chain fragment variable antibody (scFv) against ras protein, p21Ras. The anti-p21Ras scFv gene was constructed by phage display library from hybridoma KGHR1, and then subcloned into replication-defective adenovirus vector to obtain recombinant adenovirus KGHV100. Human tumor cell lines with high expression of p21Ras SW480, MDA-MB‑231, OVCAR-3, BEL-7402, as well as tumor cell line with low expression of p21Ras, SKOV3, were employed to investigate antitumor effects in vitro and in vivo. Fluorescence microscopy demonstrated that KGHV100 was able to express intracellularly anti-p21Ras scFv antibody in cultured tumor cells and in transplantation tumor cells. MTT, Transwell, colony formation, and flow cytometry analysis showed that KGHV100 led to significant growth arrest in tumor cells with high p21Ras expression, and induced G0/G1 cell cycle arrest in the studied tumor cell lines. In vivo, KGHV100 significantly inhibited tumor growth following intratumoral injection, and the survival rates of the mice were higher than the control group. These results indicate that the adenovirus-mediated intracellular expression of the novel anti-p21Ras scFv exerted strong antitumoral effects, and may be a potential method for therapy of cancers with p21Ras overexpression.
Collapse
Affiliation(s)
- Ju-Lun Yang
- Department of Pathology, Kunming General Hospital of PLA, Kunming 650032, P.R. China
| | - Xin-Yan Pan
- Department of Pathology, Kunming General Hospital of PLA, Kunming 650032, P.R. China
| | - Wen-Xing Zhao
- Department of Pathology, Kunming General Hospital of PLA, Kunming 650032, P.R. China
| | - Qi-Chan Hu
- Graduate School, Kunming Medical University, Kunming 650500, P.R. China
| | - Feng Ding
- Graduate School, Kunming Medical University, Kunming 650500, P.R. China
| | - Qiang Feng
- Department of Pathology, Kunming General Hospital of PLA, Kunming 650032, P.R. China
| | - Gui-Yun Li
- Department of Pathology, Kunming General Hospital of PLA, Kunming 650032, P.R. China
| | - Ying Luo
- Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming 650500, P.R. China
| |
Collapse
|
4
|
Ayan S, Gokce G, Kilicarslan H, Ozdemir O, Yildiz E, Gultekin EY. K-RAS mutation in transitional cell carcinoma of urinary bladder. Int Urol Nephrol 2002; 33:363-7. [PMID: 12092657 DOI: 10.1023/a:1015213713048] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
In the present study it was aimed to investigate the frequency of K-RAS mutation in the human bladder transitional cell carcinoma. For this purpose, tissue specimens obtained from the patients with bladder tumors. Genomic DNAs were isolated and then PCR-SSCP analysis of K-RAS gene were performed. A heterozygous deleted mutation was detected in K-RAS oncogene (exon 2) in agarose gel electrophoresis in one patient and point or substitution mutations are detected using single strand conformational polymorphism (SSCP) in other different patients with bladder cancer (4/14). In conclusion, the frequency of K-RAS mutation is not rare and the role of this mutation in oncogenesis and in infiltration of the urinary bladder wall needs to be confirmed in a larger study.
Collapse
Affiliation(s)
- S Ayan
- Department of Urology, Medical Biology and Genetics and Pathology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
| | | | | | | | | | | |
Collapse
|
5
|
Ayan S, Gokce G, Kilicarslan H, Ozdemir O, Yildiz E, Gultekin EY. K-RAS mutation in transitional cell carcinoma of urinary bladder. Int Urol Nephrol 2002. [PMID: 12092657 DOI: 10.1023/a: 1015213713048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
In the present study it was aimed to investigate the frequency of K-RAS mutation in the human bladder transitional cell carcinoma. For this purpose, tissue specimens obtained from the patients with bladder tumors. Genomic DNAs were isolated and then PCR-SSCP analysis of K-RAS gene were performed. A heterozygous deleted mutation was detected in K-RAS oncogene (exon 2) in agarose gel electrophoresis in one patient and point or substitution mutations are detected using single strand conformational polymorphism (SSCP) in other different patients with bladder cancer (4/14). In conclusion, the frequency of K-RAS mutation is not rare and the role of this mutation in oncogenesis and in infiltration of the urinary bladder wall needs to be confirmed in a larger study.
Collapse
Affiliation(s)
- S Ayan
- Department of Urology, Medical Biology and Genetics and Pathology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
The use of biomarkers is increasing both in acute and chronic disease epidemiology, but the rationale for their introduction is not always firmly established (e.g., when and how their use is scientifically justifiable and cost effective). The use of biomarkers should be considered within the context of causal models in epidemiology, and of the intertwining of causation and pathogenesis. Unlike infectious diseases, for cancer and cardiovascular disease external "necessary" causes have not been identified. Thus, the classification of cancer and other chronic diseases cannot be based on unequivocal criteria such as the "etiologic" classification of infectious diseases. As far as morphology is concerned, "neoplasia" and "anaplasia" are attributes of cancer that cannot be defined in a straightforward way. Tissue pathologies are minimal and difficult to differentiate from normal tissue in some cancers but are obvious in others. From a mechanistic point of view, unless molecular biology discovers specific mechanistic steps in carcinogenesis, which indicate the existence of "necessary" events in carcinogenesis, we cannot adopt an unequivocal definition of cancer. The potential contribution of biomarkers to the elucidation of the pathogenetic process should be considered in the light of such uncertainties. There is a range of indications for biomarkers, from the use of very specific measurements aimed at single molecules, to measurements indicating cumulative exposure to agents with the same mechanism of action. The potential uses of markers in chronic disease epidemiology include (1) exposure assessment in cases in which traditional epidemiologic tools are insufficient (particularly for low doses and low risks); (2) multiple exposures or mixtures, in which the aim is to disentangle the etiologic role of single agents; (3) estimation of the total burden of exposure to chemicals having the same mechanistic target; (4) investigation of pathogenetic mechanisms, and (5) study of individual susceptibility (e.g., metabolic polymorphism, DNA repair).
Collapse
Affiliation(s)
- P Vineis
- Institut Municipal D'Investigació Mèdica, Universitat Autònoma de Barcelona, Spain
| | | |
Collapse
|